Get the latest news, insights, and market updates on TEVA (Teva Pharmaceutical Industries Limited). Explore the news page 5 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Is Teva a Bargain After 27% Surge and Cost-Cutting Headlines?
Wondering if Teva Pharmaceutical Industries is now a bargain or if you might be late to the party? You're not alone. Investors are searching for value in a market where expectations are shifting fast. Teva's stock has climbed 2.3% over the past week and 27.4% in the last month. This adds up to a 50.8% gain over the past year and a 184.9% return in three years. Recent headlines have put Teva in the spotlight due to its progress with cost-cutting initiatives and a stronger balance sheet, which... Nov 26, 2025 - $TEVA
European Biosimilar Approvals Could Be a Game Changer for Teva Pharmaceutical Industries (TEVA)
In recent days, Teva Pharmaceutical Industries received European Commission marketing authorizations for its denosumab biosimilars, PONLIMSI and DEGEVMA, which target bone health treatments across Europe. This regulatory milestone aligns with Teva’s Pivot to Growth strategy and enables the company to expand its biosimilars portfolio in key European markets. We'll now explore how these European biosimilar approvals may influence Teva's future growth trajectory and overall investment... Nov 26, 2025 - $TEVA
Why Analysts See Teva’s Story Shifting With New Approvals and Rising Price Targets
Teva Pharmaceutical Industries stock has drawn renewed attention after consensus analyst price targets edged higher, rising from $27.45 to $27.90 per share. This subtle adjustment reflects a blend of cautious optimism, influenced by both regulatory developments and performance expectations. As analysts weigh potential growth opportunities alongside persistent industry risks, readers will want to follow closely to stay informed on the evolving narrative shaping Teva’s outlook. Analyst Price... Nov 25, 2025 - $TEVA
Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®
Following the positive opinions of the Committee for Medicinal Products for Human Use (CHMP), the European Commission has granted marketing authorizations for Teva’s biosimilars PONLIMSI and DEGEVMA expanding access to important bone health treatments across Europe These approvals mark another significant milestone in Teva’s strong biosimilars portfolio, in line with Teva's Pivot to Growth StrategyThe approvals underscore Teva’s commitment to broadening access to biosimilars TEL AVIV, Israel, No Nov 25, 2025 - $TEVA
This Investor Beat the Market for 3 Decades Without a Single Losing Year. 3 Stocks He’s Buying Now.
Stanley Druckenmiller has been one of the most successful investors, a billionaire with a long record of high returns in global macro investing. He’s now piling into Natera (NASDAQ:NTRA), Insmed (NASDAQ:INSM), and Teva Pharmaceutical (NYSE:TEVA). They’re worth looking into, as Druckenmiller has an exceptional record. In 1977, Druckenmiller started his financial career as an oil ... This Investor Beat the Market for 3 Decades Without a Single Losing Year. 3 Stocks He’s Buying Now. Nov 24, 2025 - $TEVA
Teva seeks startups to help solve global pharmaceutical challenges
JERUSALEM (Reuters) -Teva Pharmaceutical Industries said on Wednesday it was calling on startups to join its new platform to develop technologies to deal with a host of challenges facing Teva and the global pharmaceuticals industry. Called Teva Rise, the company's open innovation platform aims to accelerate innovations such as AI, digital health, smart manufacturing and biotech, and will connect startups and tech companies with Teva's business units, it said. Nov 19, 2025 - $TEVA
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple